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Pain is a common complaint of patients in the dental clinic. Patient with dental 
orofacial pain usually presents with hyperalgesia and allodynia. Its management 
has been a challenge, especially in the status of chronic pain or neuropathic pain. 
Purinergic signaling is dictated by ATP release, purinergic receptors activation, 
and sequential hydrolysis of ATP. Purinergic signaling participates in nociception 
processing in the sensory nerves by control of pain signal transduction, modula-
tion, and sensitization. Since purinergic receptors are preferentially expressed in 
trigeminal nerves, purinergic singling may play a crucial role in the development 
of dental orofacial pain. In this chapter, we overview the expressions of purinergic 
receptors as well as the machinery for ATP release, ATP degradations, and adenos-
ine generation in trigeminal nerves. Specifically, the roles of ATP signaling in dental 
orofacial pain generation and central sensitization via activation of P2 receptors 
and adenosine signaling in analgesia via activation of P1 receptors in trigeminal 
nerves are updated. We also discuss the affection of ecto-nucleotidases, the major 
enzymes responsible for extracellular ATP degradation and adenosine generation in 
trigeminal nerves that drive the shift from ATP-induced pain to adenosine-induced 
analgesia. This chapter provides advanced outlines for purinergic signaling in 
trigeminal nerves and unveils potential therapeutic targets for the management of 
dental orofacial pain.
Keywords: trigeminal nerves, orofacial pain, dentine hypersensitivity,  
central sensitization, analgesia, antinociception, dental pulp, P1 receptor,  
P2 receptor, ecto-nucleotidases, NTPDases
1. Introduction
Pain is an unpleasant sensation of subjects to harmful or potential harmful 
stimulations. Trigeminal nerves mediate orofacial somatosensory sensations, 
including dental orofacial pain. The primary trigeminal ganglia nociceptive neurons 
send axonal fibers innervating orofacial tissues as well as forming synapses with 
secondary nociceptive neurons in the brainstem. Noxious stimuli, biological insults, 
or pain mediators released following tissue injury and inflammations activate the 
nociceptors resulting in the nociceptive transduction in peripheral sensory nerves. 
The pain signal is conducted and further transmitted to the secondary and higher 
level nociceptive neurons via synaptic transmission in the brain. Nociception also 
depends on the condition and status of the sensory nervous system. Pain signal 
processing can be facilitated with maladaptive plasticity or neuropathy changes in 
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the nociceptive pathway that result in pain sensitization or neuropathic pain. These 
changes include nociceptive sensitization, malfunctioned inhibition, and circuit-
level rewiring/aberrant processing [1] in both the peripheral and central nocicep-
tive nerves. As peripheral or central sensitization occurs, slight noxious stimulation 
or even non-noxious stimulation induces severe pain, a phenomenon that is called 
hyperalgesia or allodynia, respectively. In sensitization condition, patients may 
also present with spontaneous and neuropathic pain without apparent stimulus. 
In contrast to the pain from extra-orofacial regions, dental orofacial pain is usu-
ally accompanied by the presence of hyperalgesia, allodynia. Dental orofacial pain 
patients often experience more severe pain and are typically emotional-distracted. 
Besides, patients with dental orofacial pain are prone to develop spontaneous pain, 
referred pain, and neuropathic pain [2].
For the past decades, studies strongly suggest a key modulatory role of puriner-
gic signaling in pain generation and sensitization in the nociceptive nerves [3–7]. 
ATP induces pain via activation of P2X receptors in peripheral sensory nerve fibers. 
ATP is also involved in cross-talk between the primary and secondary nociceptive 
neurons as well as with astrocytes and microglia. Since ATP and its metabolites are 
pain mediators and participate in pain signal processing via activation of various 
purinergic receptors (P1 and P2 receptors) in the nociceptive sensory nerves [5, 8–10], 
one putative explanation for the unique properties in dental orofacial pain is due to 
the different existence or expression of purinergic signaling in trigeminal nerves. 
Indeed, it has been observed that purinergic receptors are preferentially expressed 
in trigeminal nociceptive neurons compared with that in dorsal root ganglions 
[11, 12]. Purinergic signaling depends on ATP release, purinergic receptors (P1, 
P2X, and P2Y) activation, and extracellular enzymatic ATP degradation and 
adenosine generation. Therefore, identification of the machinery components for 
purinergic signaling in the trigeminal nociceptive pathway will provide promising 
insight to understand the underlying nociceptive mechanisms for the pathogenesis 
of dental orofacial pain.
In this chapter, we overview the expression of purinergic receptors and machin-
ery for ATP release, ATP degradation, adenosine generation in the trigeminal 
nociceptive nerves, and discuss the role of purinergic signaling in the pathogenesis 
of dentin hypersensitivity and dental orofacial pain. Understanding the role of 
purinergic signaling in the nociceptive mechanisms for pain signal transduction, 
transmission, sensitization, and modulation in trigeminal nerves will reveal mul-
tiple targets for developing more effective drugs and therapies for the management 
of dental orofacial pain.
2. Purinergic signaling and pain
2.1 ATP initiates pain signal via activation of peripheral P2X receptors
ATP has been recognized as a neuronal transmitter and modulator in synaptic 
transmission for decades [13]. ATP and its metabolites are also important pain 
mediators and modulators in pain signal processing [5, 8–10]. It has been proposed 
that ATP released from various cell types is implicated in initiating the pain signal 
by acting on purinoceptors on sensory nerve terminals [14]. Purinoreceptors 
responsible for pain transduction belong to P2X receptor family, a group of ligand-
gated non-selective cation channels using ATP as a native agonist. Upon binding 
to P2X receptors, ATP opens the pore of channels permeable to Na+, K+, and Ca2+ 
that depolarize the membrane potential, enhance the excitability and induce spikes 
in nociceptive neurons. So far, seven distinct P2X receptor subunits (P2X1–P2X7) 
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have been isolated and cloned (North 2002). A total of 14 functional homo- or 
heterotrimers P2X receptors (P2X1–P2X7, P2X1/2, P2X1/4, P2X1/5, P2X2/3, 
P2X2/6, P2X4/6, and possibly P2X4/7) assembled from different subunits had been 
reported [15].
Using in situ hybridization immunohistochemistry (ISHH), mRNA expression 
for P2X2, 3, 4, 5, and 6 receptors had been detected in naive dorsal root ganglia 
(DRG) neurons, in which P2X2 and P2X3 receptors were expressed preferentially 
by C-fiber neurons. In contrast, the majority of P2X5 and P2X6 receptors were 
preferentially expressed by A-fiber neurons [16]. Specifically, expression of P2X 
receptors is also detected in nociceptive primary sensory neurons, peripheral noci-
ceptive nerve fibers, and their free endings extending throughout the epidermis. 
Two types of P2X receptors (P2X2 and P2X3) have been particularly examined in 
DRG presumably nociceptive neurons [17]. P2X3 receptors appear to be exclusively 
expressed in a subgroup of sensory neurons that are likely to be nociceptive neurons 
[18]. Nociceptive neurons fall into nerve growth factor (NGF) sensitive group and 
glial cell-line derived neurotrophic factor (GDNF) sensitive group. It turned out 
that the vast majority of P2X3 positive neurons overlap with GDNF subgroup of 
nociceptive neurons [19]. P2X3 receptors are peripherally axonal transported and 
have been identified in the free end of the nerve fibers in a variety of tissues includ-
ing tongue, skin, and viscera (e.g., bladder) [17, 19]. Co-localization studies suggest 
that many, but not all, DRG cells that express P2X2 receptors also express P2X3 
receptors [17]. Furthermore, electrophysiological and pharmacological studies had 
demonstrated that the application of ATP or its analogs to DRG neurons results in 
depolarization or inward currents mediated by P2X receptors activation.
The selective expression of P2X3 and P2X2 receptors within the nociceptive 
nerves has inspired a variety of approaches to elucidate the potential role of ATP as 
a pain mediator. ATP elicits excitatory inward currents in nociceptive small diam-
eter sensory ganglion cells. Interestingly, these inward currents resemble the cur-
rents evoked by ATP on recombinantly expressed heteromeric P2X(2/3) channels 
as well as homomultimers consisting of P2X2 and P2X3 [8, 14, 18, 20]. It had been 
observed that ATP and its analogs produce spike activity when applied to peripheral 
nociceptive terminals [8]. In in vivo pain behavioral animal models, the algogenic 
effects of ATP in normal conditions and models of peripheral sensitization had been 
confirmed. In humans, local skin delivery of ATP induces dosage-dependent pain 
sensation. Furthermore, it has been shown that ATP-induced algogenic responses 
depends on capsaicin-sensitive neurons and is augmented in the presence of inflam-
matory mediators. Since ATP is released in the vicinity of peripheral nociceptive 
terminals under a variety of conditions such as tissue injury or inflammation, the 
existence of purinergic signaling in peripheral sensory nervous free ends strongly 
links the tissue damage and inflammation to pain perception [9].
2.2 Purinergic signaling is involved in central sensitization
Noxious stimulation to the nociceptive nerves induces pain sensation in the 
brain. Acute pain is a warning signal for the individual to survive in response to 
tissue injuries or diseases. However, in nociceptive sensitization statuses, such as 
in chronic pain or neuropathic pain, nociception no longer relates to or depends on 
external noxious stimulation, and slight noxious or even no-noxious stimulation or 
non-stimulation at all can induce severe pain. The central sensitization theory pro-
posed that neuronal plasticity occurred in the sensory nerve circuits that enhance 
the sensitivity to noxious stimuli or even turn the innocuous slight touching to 
pain [21]. Pain sensitization can also be induced by nerve injury (deafferentation, 
compression, and constriction) or neuropathy changes resulting from physical, 
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chemical, metabolic, or biological insults to the sensory nerves. Besides, it has been 
proposed the pain signal itself that is accompanied with releasing of proinflam-
matory cytokines, neuronal transmitters, and modulators in nociceptive neuronal 
circuits participate in plasticity changes and induce central sensitization [22].
Synaptic neuronal transmission is accompanied with large amount of ATP 
release. Accumulated evidence suggests that ATP signaling play an essential role in 
the development and maintenance of central sensitization (Figure 1) [3–7]. In the 
somatosensory nerves, P2X receptors are expressed in DRG nociceptive neurons 
and then transferred to central axonal terminals as well as peripheral free ends. 
For example, immunoreactivity to P2X3 subunits is detected in lamina IIi in spinal 
cord dorsal horn and is disappeared after axotomy or following destruction of 
IB4-positive afferent fibers [17]. Immunoreactivity to P2X1 and P2X2 subunits are 
also located on the central terminals of primary afferent neurons that innervate 
superficial lamina of the spinal cord dorsal horn [17]. The presence of P2X receptor 
subunits at the central terminals of primary afferent neurons raises the possibil-
ity that ATP may act on central terminals of primary afferent neurons to either 
modulate or directly evoke the release of neuronal transmitters such as glutamate 
and neuropeptides. Activation of central terminal P2X receptors will depolarize the 
membrane potential and induce Ca2+ influx that will enhance the release of gluta-
mate and substance P, and subsequently increase the secondary nociceptive neuron 
responses and dorsal horn nociceptive output. In neuropathic pain condition, an 
increase in the number of P2X receptors positive DRG neurons is observed follow-
ing sciatic nerve injury by chronic constriction [23]. Specifically, an increase of 
P2X3 receptor immunoreactivity is detected in the dorsal horn ipsilateral side of the 
injured nerve indicating the upregulation of P2X receptors at the central terminals 
of primary afferent neurons. P2X receptor expression is also upregulated follow-
ing tissue injury or inflammation within the spinal cord. The upregulation of P2X 
receptor expression on the central terminals of primary afferent neurons would 
sensitize the responses to ATP, which in turn may facilitate P2X receptor-mediated 
nociceptive modulation.
Activation of homomeric, as well as heteromeric P2X2/3 receptors, appears 
to modulate longer lasting nociceptive sensation associated with nerve injury or 
chronic inflammation [1]. P2X3 receptor function is highly sensitive to soluble fac-
tors like neuropeptides and neurotrophins and is controlled by transduction mecha-
nisms, protein-protein interactions, and discrete membrane compartmentalization. 
Recent findings have demonstrated that P2X3 receptors interact with the synaptic 
scaffold protein calcium/calmodulin-dependent serine protein kinase (CASK) in a 
state-dependent fashion, indicating that CASK plays a crucial role in the modula-
tion of P2X3 receptor stability and efficiency [24]. Activation of P2X3 receptors 
within CASK/P2X3 complex has essential consequences for neuronal plasticity and 
possibly for the release of neuromodulators and neurotransmitters. Better under-
standing the interaction machinery for P2X3 receptors and their integration with 
other receptors and channels on pre- and postsynaptic membranes is proposed to be 
essential to unveil the process of nociceptive neuronal sensitization.
Multiple other purinoceptor subtypes participate in pain processing. In neuro-
pathic pain, activation of purinergic receptors on microglia is thought to maintain 
nociceptive sensitization through neural-glial cell interactions [3]. Microglia 
expresses several P2 receptor subtypes, and of these the P2X4, 7, and P2Y12 recep-
tor subtypes have been implicated in neuropathic pain. It has been shown that 
activation of P2X4, 7, and P2Y12 receptors expressed on microglia is critically 
involved in neuropathic pain arising from peripheral nerve injury [25], while 
blocking these receptor with antagonists reduces neuropathic pain [3]. The P2X4 
receptor has emerged as the core microglia-neuron signaling pathway. In response 
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to peripheral nerve injury, P2X4 receptors are upregulated in spinal cord microglia 
[26]. Activation of this receptor causes the release of brain-derived neurotrophic 
factor (BDNF) which causes disinhibition of pain-transmission neurons in spinal 
lamina I. Several mechanisms have recently been implicated in the upregulation 
of P2X4 receptors including CCL21, interferon γ, tryptase, fibronectin, and the 
activation of μ-opioid receptors. Activation of P2X4 receptors leads to an influx of 
extracellular Ca2+ activating p38 MAPK that leads to SNARE-dependent release of 
BDNF from the microglia. BDNF is a crucial microglia-neuron signaling molecule 
that causes disinhibition of nociceptive dorsal horn neurons by disrupting intracel-
lular Cl− homeostasis of inhibitory interneurons [27–29]. Activation of P2X7 or 
P2Y12 receptors is also through signals of p38 MAPK. p38 MAPK signaling drives 
the release of interleukin-1β and cathepsin S, which contributes to the maintenance 
of mechanical hypersensitivity in the spinal cord. P2Y12 receptor expression is 
also upregulated in microglia, and activation of these receptors is involved in 
neuropathic pain. Recent studies have demonstrated that inhibition of microglia-
expressed P2 receptors (P2X4, P2X7 or P2Y12) by the pharmacological blockade, 
antisense knockdown or genetic deletion suppresses both mechanical allodynia and 
thermal hyperalgesia in nerve-injured rats [30, 31]. Conversely, intrathecal admin-
istration of the P2Y12 receptor agonist 2Me-SADP elicits pain behaviors in naïve rats 
that mimic those observed in nerve-injured rats [30].
2.3 Adenosine induces antinociception by activation of P1 receptors
In contrast to the algogenic effects of ATP, adenosine, the metabolite of ATP, 
induces antinociception via activation of P1 receptors. P1 receptors are G protein-
coupled metabotropic receptors. Four subtypes of P1 receptors (A1, A2A, A2B, and 
A3) have been cloned in the nervous system [32].
A1 receptor is detected in the peripheral sensory nerve fibers [33]. Local delivery 
of adenosine induces analgesia and blocking A1 receptors abolishes adenosine-
induced antinociception in various inflammatory pain models [34]. In addition, it 
has been shown that adenosine also mediates the analgesic mechanism of acupunc-
ture via peripheral A1 receptors [35]. Adenosine also produces antinociception via 
activation of A1 receptors in the spinal cord [33]. Intraspinal injection of adenosine 
or A1 receptor agonists induced antinociception in both inflammatory and neuro-
pathic pain animal models. It has been proposed that the underlying mechanism 
for adenosine-induced antinociception is related to potassium channel activation-
induced cell membrane hyperpolarization [36]. Activation of pre- or postsynaptic 
A1 receptor triggers cAMP/PKA, PLC/IP3/DAG, and nitric oxide/cGMP/PKG 
pathways [33, 37] that induce analgesia by reducing presynaptic vesicle release and 
postsynaptic excitability [36]. Indeed, it has been demonstrated that A1 recep-
tor activation decreased the excitatory neurotransmitter release in synaptosomes 
isolated from the spinal cord dorsal horns [38, 39].
Endogenous adenosine also mediates antinociception by A2A, A2B, or A3 
receptors expressed in nociceptive neurons, astrocytes, or immune cells [40, 41]. 
Considering the extensive involvements of glial cells (microglia and astrocytes) in 
central sensitization and chronic pain [42], activation of adenosine receptors on 
microglia and astrocytes are potentially involved in the antinociceptive mechanism 
of adenosine in the nervous system [43]. Additionally, adenosine may also mediate 
the antinociception by enhancing GABA inhibition and blocking neuroinflamma-
tion via activation of A3 receptors [44]. Collectively, these studies suggest the pos-
sibility of treating chronic pain by targeting specific adenosine receptor subtypes in 
anatomically defined regions with agonists or with ecto-nucleotidases that control 
the generation of adenosine.
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2.4  Ecto-nucleotidases drive the shift from ATP-induced pain to  
adenosine-induced antinociception
Purinergic signaling depends on ATP release, purinergic receptor action, and 
sequential hydrolysis of ATP to ADP and nucleoside adenosine [45]. Because of 
their dynamic catalytic activities under physiological conditions, ecto-nucleotide 
diphosphatases (Ecto-NTPDases) are the major enzymes responsible for the 
hydrolysis of extracellular ATP and ADP. Four members of ecto-NTPDse family 
(NTPDase1, 2, 3, and 8) have been cloned. Three of which (i.e., NTPDase1, 2, 
and 3) are expressed in the nervous system [46]. NTPDase1 and 3 hydrolyze both 
ATP and ADP, while NTPDase2 primarily hydrolyzes ATP with minimal ADP 
hydrolytic activity [47]. Extracellular AMP is further hydrolyzed to adenosine by 
ecto-5′-nucleotidase (CD73) [47, 48] and a transmembrane isoform of prostatic acid 
phosphatase (PAP) [47, 48] in the nervous system. By control of ATP degradation 
and adenosine generation, these ecto-nucleotidases affect nociception by terminat-
ing ATP-induced pain and pain sensitization and promoting adenosine-mediated 
analgesia.
ATPase activity had been detected in dorsal root ganglion (DRG) and spinal 
cord using enzymatic histochemistry staining. Nucleotidase activity is robust in spi-
nal cord dorsal horn nociceptive lamina suggesting that nucleotide hydrolysis would 
play a role in nociceptive processing. In DRG, extensive staining revealed ecto-
ATPase activity in a subset of neurons and non-neuronal cells. The mRNA expres-
sion and immunoreactivity for NTPDase1–3, but not NTPDase8, was detected in 
lumbar DRG and spinal cord. Immunoreactivity for NTPDase3 that closely matches 
the distribution of ecto-ATPase activity labels DRG central projections in the dorsal 
root and superficial dorsal horn, as well as intrinsic spinal neurons concentrated 
in lamina II. It has been reported that NTPDase3 is located in nociceptive and 
non-nociceptive neurons of DRG, in the dorsal horn of the spinal cord, and the 
free nerve endings in the skin [49]. These data suggest that NTPDase3 would be a 
negative regulator for nociceptive signaling [50]. However, studies from NTPDase3 
knockout mouse show that deletion of NTPDase3 does not impair ATP hydrolysis in 
primary somatosensory neurons or dorsal spinal cord. Also, NTPDase3 (−/−) mice 
did not differ in nociceptive behaviors when compared with wild-type mice. These 
observations suggest the existence of multiple ecto-nucleotidases acting redun-
dantly to hydrolyze nucleotides [49].
Even though the manipulation of adenosine transport or degradation can 
induce antinociception [51], extracellular adenosine level is mainly controlled by 
extracellular AMP hydrolysis. Indeed, it has been shown that extracellular AMP 
hydrolysis provides the major source for endogenous adenosine in the nervous 
system that is essential to maintain a tonic activation of adenosine receptors in 
the nociceptive neurons of the spinal cord [52]. Two ecto-nucleotidases have been 
identified to be responsible for extracellular AMP hydrolysis in the spinal cord 
[48]. Ecto-5′-nucleotidase (CD73) is a membrane-anchored protein that hydro-
lyzes extracellular adenosine 5′-monophosphate (AMP) to adenosine in different 
tissues. CD73 was detected in peptidergic and nonpeptidergic nociceptive neurons 
in DRG and afferent terminals in lamina II of spinal cord. In addition, CD73 was 
also located on epidermal keratinocytes, cells of the dermis, and on nociceptive 
terminals in the epidermis [52]. Besides CD73, prostatic acid phosphatase (PAP) 
also functions as an ecto-nucleotidase and generates extracellular adenosine. PAP 
is expressed in nociceptive dorsal root ganglia (DRG) nociceptive neurons, it had 
been shown that PAP inhibits noxious thermal sensitivity and sensitization that 
is associated with chronic pain through sustained activation of the adenosine A1 
receptor [53].
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Knockout of CD73 and/or PAP reduced adenosine generation and enhanced noci-
ception in animal models following inflammation and nerve injury [52]. It has been 
found that AMP hydrolysis was nearly abolished in DRG neurons and lamina II of the 
spinal cord from PAP/CD73 double knockout (dKO) mice. Likewise, the antinocicep-
tive effects of AMP were reduced in PAP/CD73 dKO mice. Adenosine was maximally 
produced from AMP within seconds in wild-type (WT) mice but was significantly 
reduced in dKO mice indicating PAP and CD73 generate rapidly adenosine in lamina 
II. Besides, it has shown the existence of spontaneous low-frequency adenosine tran-
sients in lamina II in wild-type mice, while knockout of PAP and CD73 abolished the 
spontaneous adenosine transit suggesting these ecto-nucleotidases rapidly hydrolyze 
endogenously released nucleotides to adenosine, and there exists tonic activation of 
A1 receptors. Field potential recordings in dorsal horn lamina II and behavioral stud-
ies indicated that adenosine converted by these enzymes acts through the A1 receptor 
to inhibit excitatory neurotransmission. PAP and CD73 injected spinally produced 
long-lasting adenosine A1 receptor-dependent antinociceptive effects in inflamma-
tory and neuropathic pain models [54]. Furthermore, it has been noted that following 
peripheral nerve injury CD73, PAP, as well as enzymatic ecto-AMPase activities were 
reduced in dorsal horn lamina II. Collectively, these evidences indicate that PAP and 
CD73 are the predominate ecto-nucleotidases that generate adenosine in the nocicep-
tive circuits (Figure 1) [48].
Figure 1. 
Schematic illustrates purinergic signaling responsible for the pain signal transmission and sensitization at the 
nociceptive synapses. (1) Primary nociceptive inputs promote glutamate and ATP co-release and synergistically 
cause non-selective permeability to Ca2+, Na+, and K+ cations via P2X3 receptor, leading to postsynaptic 
activation of NMDA or AMPA receptors and further contributing astrocytic glutamate and ATP co-release into 
the extracellular milieu which result in the pain signal transmission in the nociceptive synapses. (2) Activation 
of P2X4/7 receptors expressed on astrocytes and microglia induces a local inflammatory response with release 
of cytokines including IL-1β, BDNF, and TNF-α, which will lead to sensitization in pain signal transduction 
and conduction as well as synaptic transmission caused by enhanced excitatory and reduced inhibitory driving. 
(3) Activation of A1 receptor triggers multiple intracellular cAMP/PKA, PLC/IP3/DAG, and nitric oxide/
cGMP/PKG signaling and induces analgesia by reducing both presynaptic vesicle release and postsynaptic 
excitability. Adenosine may also mediate antinociception by activation of A2A, A2B, or A3 receptors expressed 
on nociceptive neurons, astrocytes, or immune cells. (4) Ecto-nucleotidases (NTPDase3/CD73) are specifically 
expressed in primary nociceptive neurons and localized at presynaptic terminals that will drive the shift from 
ATP-induced pain to adenosine-mediated analgesia by control of extracellular ATP extracellular hydrolysis in 
the nociceptive pathway [99].
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3. ATP signaling and dentin hypersensitivity
3.1 Dentin hypersensitivity
Dentin hypersensitivity (DHS) is defined as a short, sharp pain that arises 
from exposed dentin in response to various environmental stimuli [55–57]. 
Dentin exposure can be caused by physical, chemical, pathological, biological 
challenges, and/or developmental abnormalities that result in dental and or peri-
odontal damage or defects. In patients with DHS, gentle touch, mild cold or hot, 
chemical (acidic or sweet fruits, foods, and drinks) or air-flow stimulation to the 
exposed dentine can induce similar short, sharp pain. DHS can affect the quality 
of patient’s daily activities such as eating, drinking, speaking, and tooth brushing. 
In some cases, more severe DHS can become a constant annoyance and induce 
psychological and emotional distractions [55, 57]. Even though DHS is a com-
mon problem, the underlying nociceptive transduction mechanism still remains 
elusive, and no universally accepted or highly reliable desensitizing agents or 
treatment are available in dental practice.
3.2 Hydrodynamic theory
It is generally regarded that DHS is associated with dentin exposure, especially 
the exposure of open dentinal tubules, and dental pulp nerve responsiveness to 
external environmental stimuli [58]. Several theories have been proposed for 
the pathogenesis of DHS. The most widely accepted one is the hydrodynamic 
theory that is introduced by Brannstrom in 1964 [59]. It stated that environmental 
mechanical, thermal, or chemical changes cause the movements of fluid within 
dentinal tubules that stimulate the terminals of pulpal nerve fibers located at the 
dentin tubule inlets, thereby induces transient acute pain. The hydrodynamic 
theory highlights the notion that several different stimuli can evoke similar 
responses via dentin tubule fluid movements. The intra-dental myelinated Aβ 
fibers and some Aσ fibers that send terminals into the dentin tubules are thought 
to respond to the fluid movements resulting in the characteristic short, sharp pain 
of DHS. However, Aβ fibers usually mediate slight touching sensation with a lower 
threshold to mechanical stimulation, while Aσ fibers mediate pain, but they exhibit 
high threshold to noxious stimulation. How the essentially non-noxious dentin 
tubule fluid movements induce the nociceptive transduction in dental pulpal nerve 
fibers remains an enigma. Recently, the hydrodynamic theory has been challenged 
by emerging evidence suggesting that odontoblasts might play an essential role in 
the nociceptive transduction of DHS [60–62].
3.3 The machinery for ATP signaling in dental pulp
Odontoblasts locate at the outermost layer of the dental pulp and send odonto-
blastic processes to the dentin tubules. Therefore, odontoblasts are the first dental 
pulp cells to detect external stimuli in dentin exposure. Though a physical synaptic 
structure is absent, dental pulp nerve fibers are closely approached to the odonto-
blasts and tightly entangle these cells. This finding could provide a mechanism to 
explain how signals are transmitted to adjacent nerve endings through chemical 
mediators released from the odontoblasts. That is, a paracrine cell-cell commu-
nication is involved in signal transmission as opposed to classic neural synapses. 
Since purinergic P2X3 receptors are expressed in dental pulp nerve fibers [63] and 
activation of P2X receptors in peripheral nerve fibers induces pain [9]. ATP has 
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been proposed as a promising candidate that participates in cell-cell communication 
within the dental pulp that would be associated with pain transduction mechanism 
of DHS [64].
For the past decades, chemo-, mechano-, and or thermo-sensitive channels 
such as connexin, pannexin, TRPV1-4, TRPM3, KCa, TREK-1, beta-ENa(+) C, 
and ASIC2 channels have been identified in odontoblasts [60, 65–70]. Activation 
of these channels depolarizes the membrane potential that induces ATP release 
via vesicles release or channel opening in odontoblasts. Interestingly, mechanic- 
as well as depolarization-sensitive ATP permeable channel such as connexin 
43 and pannexins had been detected in odontoblastic processes inserting into 
dentinal tubules [60, 64]. Indeed it has been shown that mechanical and or 
thermal stimulation that mimics dentin hypersensitivity in clinic induces ATP 
release from odontoblasts [65, 66, 71]. Besides, mechanical stimulation-induced 
ATP release and ATP-mediated signal transmission from odontoblasts to trigemi-
nal neurons have been demonstrated in vitro using co-culture models comprising 
of odontoblasts and trigeminal neurons [68, 72]. The existence of autocrine/
paracrine mechanisms for ATP-involved purinergic signaling in cultured odon-
toblast-like stem cells is also confirmed [73]. Furthermore, external mechanical 
and thermal stimulation that mimics dentin hypersensitivity induces ATP release 
in a tooth perfusion model, while pharmacological blocking connexin and pan-
nexin channels abolished external stimulation-induced ATP release in dental 
pulp [66]. Based on the above observations, we proposed that, as illustrated in 
Figure 2, external stimulation-induced mechanosensitive responses and ATP 
release from odontoblasts and subsequently activation of purinergic receptors in 
dental pulpal nerves may represent a novel explanation as to how odontoblasts 
participate in a mechanosensory mechanism leading to the pain transduction in 
DHS [60, 74].
Figure 2. 
A novel hypothesis for nociception transduction in DHS. External stimulation-induced dentin tubule fluid 
movements induces ATP release via pannexin/connexin channels in OBs (odontoblasts), ATP then activate P2X 
receptors on adjacent nerve fibers to trigger the transduction of pain. ATP signaling is terminated by ecto-
ATPases in OBs and Schwann’s cells.
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3.4 Purinergic signaling and dentin hypersensitivity
Dentin-odontoblasts-nerve terminal complex represents the essential compo-
nents for the process of stimulation transducing and nociceptive transduction from 
environmental changes to pain impulse in DHS. External stimuli promote ATP 
release from odontoblasts through mechanic or depolarization-sensitive channels, 
which then initiates pain signaling via activation of P2X3 receptors in dental pulp 
nerve fibers. Functional ecto-nucleotidases in odontoblasts, dental pulp nerve 
fibers, and Schwann cells that surround the nerve fibers modulate pain transmis-
sion by control of the local concentration of extracellular ATP and adenosine. 
ATP and its metabolites may also activate the P2Y and P1 receptors via a paracrine 
mechanism to trigger intracellular Ca2+ signals that further promote ATP release in 
odontoblasts and regulate the expression of ATP permeable channels, purinergic 
receptors, and ecto-nucleotidases.
The existence of mechanical-sensitive ATP permeable connexin/pannexin chan-
nels and ATP singling in dentin-odontoblast-nerve fiber complex provides a clue 
to explain the unique characteristic of DHS, that is, the “all” or “none” property. In 
patients with DHS, a common phenomenon is that external environmental stimula-
tion induces either one sharp pain or no pain at all. A self-activated propagation of 
ATP signaling and calcium response in gap junction coupled cells as well as in tis-
sues or organs was demonstrated [75]. For example, a local mechanical stimulation 
induces connexin/pannexin channel opening, and then result in ATP release, ATP 
then activates the P2X/P2Y receptors in adjacent cells inducing intracellular Ca2+ 
increase and/or cell depolarization that further promote connexin/pannexin chan-
nels opening and ATP release in further beyond adjacent cells until all the cells are 
activated. Since odontoblasts express connexin 43 and are functionally connected 
via gap junction as a syncytium [60, 76], stimulation from locally exposed dentin 
tubules will induce a response in the whole dental pulp odontoblasts. With this 
mechanism, external stimulation will cause the full dental pulp odontoblast activa-
tion and evoke the typical “all” or “none” short, sharp pain in patients with DHS.
The existence of ecto-ATPase activity in dental pulp nerve fibers as well as in the 
odontoblast layer [60] may provide mechanisms to terminate ATP-induced pain in 
DHS. Studies have shown that NTPDase2 is expressed in odontoblasts as well as in 
Schwann’s cells that encapsulate the dental pulp nerve fibers. While NTPDase3 is 
expressed in dental pulp nociceptive nerve fibers. The presence of these enzymes in 
dental pulp provides machinery responsible for ATP degradation that may pro-
vide a mechanism to terminate the pain signaling induced by purinergic receptor 
activation in DHS. While the existence of ecto-AMPase enzymatic activities and 
expression of CD73 in nociceptive nerve fibers and odontoblasts [64] will hydrolyze 
AMP to adenosine, the latter will activate the A1 receptors and hyperpolarize the 
terminals of the dental pulp nerve fibers via opening the potassium channels that 
will help to stop any lingering of pain impulses in nerve fibers.
4. Purinergic signaling and dental orofacial pain
4.1 P2X receptors in trigeminal nerves
Activation of P2X receptors in peripheral nociceptive nerve fibers results in pain 
transduction. Interestingly it has been observed that purinergic P2X receptors are 
preferentially expressed in trigeminal nociceptive neurons [11, 12] suggesting that 
purinergic signaling might play a unique role in the generation and development 
of dental orofacial pain. Previous studies have shown expression of P2X3 receptors 
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in dental pulp nerve fibers, including the iB4 positive nociceptive fibers [63]. 
Furthermore, it had been demonstrated that activation of P2X3 and P2X2/3 recep-
tors in dental pulp is sufficient to elicit nociceptive behavioral as well as trigeminal 
brainstem neuronal activity [77]. Functional homomeric P2X3 receptor and hetero-
meric P2X(2/3) receptor are highly expressed on nociceptive trigeminal neurons, 
their contribution toward the pain mechanism in dental orofacial pain has been well 
established [78, 79]. Using real-time reverse transcription-PCR analysis, besides 
P2X3, mRNA expression for P2X1 and P2X4 was also detected in trigeminal gan-
glion neurons. Indeed, application of P2X receptors agonists, ATP, α,β-methylene 
ATP, or β, γ-methylene ATP induced neuronal Ca2+ influx and a series of selective 
antagonists for P2X1, P2X3, or P2X4 receptors inhibited these Ca2+ influx responses. 
Interestingly, expression of purinergic receptors (P2X1, 3, and 5) in trigeminal 
ganglion is upregulated in response to dental pulp inflammation-induced pain 
suggesting that these receptors may participate in the peripheral pain sensitization 
[80]. Expression of P2X receptors in trigeminal ganglion is also upregulated by oral 
facial deep tissue inflammation [11, 12]. In addition, application of P2X receptor 
agonist αβ-meATP to rat tooth pulp induces central sensitization in medullary 
nociceptive neurons, and this sensitization response can be blocked by dental pulp 
application of the P2X (1,2/3,3) receptor antagonist TNP-ATP as well as by medul-
lary application of TNP-ATP. These results suggest that the activation of peripheral 
P2X receptors in orofacial tissues plays a critical role in producing central sensitiza-
tion in medullary trigeminal subnucleus caudalis (TSNC) nociceptive neurons [81]. 
Therefore, trigeminal ganglion neurons preferentially express functional P2X1, 2/3, 
4 receptors, and activation of these receptors attributes to generation and sensitiza-
tion of dental orofacial pain [78].
Involvement of P2X receptor activation in dental orofacial pain had been 
demonstrated in various animal models. In the carrageenan-induced TMJ inflam-
matory hyperalgesia model, the P2X1, 3, and 2/3 receptor antagonist TNP-ATP, but 
not the selective P2X7 receptor antagonist A-438079, significantly reduced the pain 
behavior. These findings indicate that P2X3 and P2X2/3 receptors would be poten-
tial targets for the development of new analgesics to control TMJ inflammatory 
pain [82]. Interestingly, it has been found that the number of P2X3 receptor positive 
cells is increased in the small cell group in trigeminal ganglia, whereas there was no 
change in medium or large cell groups after TMJ CFA-injection. Retrograde tracing 
confirmed that TMJ-innervated neurons in TG exhibited P2X3 receptors. These 
observations provided evidence to support that P2X3 receptor play an essential role 
in orofacial pain induced by TMJ arthritis [83]. Pharmacological and immunohis-
tochemical studies revealed that the P2X3 receptor also plays an essential role in the 
heat hyperalgesia observed in the infraorbital nerve (IoN) ligation-induced neu-
ropathic pain model [84]. In an oral cancer pain model, injection of squamous cell 
carcinoma cells into the lower gingiva produces mechanical allodynia and thermal 
hyperalgesia. It has been observed that expression of P2X receptor, calcitonin 
gene-related peptide (CGRP)-, substance P (SP)-, and capsaicin receptor (TRPV1)-
immunoreactive cells are strikingly upregulated in the small cell group of trigeminal 
ganglia (TGs) after tumor cell inoculation [85].
Whereas there is ample evidence that purinergic P2 receptors in trigeminal 
glial cells are altered after peripheral nerve injury, there is very little information 
about the changes of P2 receptors in TG satellite glial cells (SGCs), although it 
is well established that SGCs are endowed with P2 receptors. In submandibular 
inflammation with the injection of complete Freund's adjuvant, there was a marked 
increase in the sensitivity of SGCs to ATP, with a threshold decreasing from 5 
μM to 10 nM. A similar result was observed in the intact trigeminal ganglion 
after infraorbital nerve axotomy. It had been demonstrated that the increased 
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after-inflammation response was mediated predominantly by P2X receptors. The 
enhanced responses to ATP after inflammation are primarily due to P2X2 and or 
P2X5 receptors, with a possible contribution of P2X4 receptors. It has been pro-
posed that the over 100-fold augmented sensitivity of SGCs to ATP may contribute 
to the development of chronic pain status in dental orofacial pain [86].
4.2 P2Y receptors in trigeminal nerves
Little is known about P2Y receptor expression in trigeminal nerves and their role 
in dental orofacial pain. It had been demonstrated that UTP, an agonist of P2Y2/
P2Y4 receptors, significantly decreased the mean threshold potentials for evoking 
action potentials and induced a striking increase in the mean number of spikes in 
TG neurons [87]. Because of its vital role in the control of neuronal spike onset, fast 
inactivating transient K+ channels (IA) is a key regulator of membrane excitability 
in sensory neurons. It has been shown that UTP significantly inhibited IA and the 
expression of Kv1.4, Kv3.4, and Kv4.2 subunits in TG neurons. The P2Y receptor 
antagonist suramin could reverse these effects. Furthermore, in ION-CCI (chronic 
constriction injury of the infraorbital nerve) induced neuropathic pain model, 
when blocking P2Y2 receptors with suramin or injection of P2Y2 receptor antisense 
oligodeoxynucleotides led to a long time- and dose-dependent reverse of allodynia 
[87]. Blocking P2Y2 receptors is accompanied with a significant increase in Kv1.4, 
Kv3.4, and Kv4.2 subunit expression and decrease in phosphorylated ERK expres-
sion in trigeminal ganglia. These data suggest activation of P2Y2 receptors leads 
to upregulation of ERK-mediated phosphorylation and decline of the expression 
of I(A)-related Kv channels in trigeminal ganglion neurons, which might reveal 
potential alternative targets for the treatment of trigeminal neuropathic pain [87].
Other type of P2Y receptors are also involved in the development of dental oro-
facial pain. Administration of the P2Y1, 12, and 13 receptor agonist, 2-(methylthio)
adenosine 5′-diphosphate trisodium salt hydrate (2-MeSADP), in naïve rats induced 
neuropathic pain in the tongue, as demonstrated in lingual nerve crush rats, while 
co-administration of P2Y receptor antagonists (MRS2395) to naïve MRS2395 rats 
did not result in hypersensitivity of the tongue. P2Y12 receptor had been detected in 
satellite cells of the trigeminal ganglia. In an orofacial pain model after lingual nerve 
crush, expression of P2Y12 receptors was enhanced in pERK1/2-immunoreactive 
cells encircling trigeminal ganglion neurons. Administration of a selective P2Y12 
receptor antagonist, MRS2395, attenuated tongue hypersensitivity to mechanical 
and heat stimulation and suppressed the increase in the relative numbers of calcito-
nin gene-related peptide (CGRP)-immunoreactive neurons and neurons encircled 
by pERK1/2-immunoreactive cells. These results suggest that intercellular com-
munication between activated satellite cells and CGRP-immunoreactive neurons via 
P2Y12 receptors contributes to the development of orofacial neuropathic pain [88].
4.3 Purinergic signaling in trigeminal subnucleus caudalis (TSNC)
Besides purinergic receptors expressed in the central afferent terminals of 
primary trigeminal nociceptive neurons, multiple P2X, P2Y, and P1 receptors are 
also detected in the secondary nociceptive neurons, astrocytes, and microglia in 
TSNC. Since pain signal synaptic transmission is accompanied by a large amount of 
ATP release in TSNC. Activation of purinergic receptors expressed in presynaptic 
afferent terminals, secondary nociceptive neurons, astrocytes, and microglia in 
TSNC would play an essential role for the development of central sensitization [77]. 
Studies have shown that extracellular ATP acting on presynaptic purinergic receptors 
(P2X2/3 and P2X3 subunits) participate in central sensitization of dental orofacial 
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pain. Application of inflammatory irritant mustard oil (MO) to the tooth pulp 
produced a long-lasting allodynia and hyperalgesia. Intrathecal administration of the 
selective P2X1, P2X3, and P2X2/3 receptor antagonist, TNP-ATP, significantly and 
reversibly attenuated the MO-induced central sensitization. While the administra-
tion of the selective P2X1, P2X3, and P2X2/3 receptor agonist, alpha, beta-methylene 
ATP (alpha, beta-meATP, i.t.) produced abrupt and significant neuroplastic changes 
in TSNC nociceptive neurons, followed by neuronal sensitization as evidenced by 
the ineffectiveness of a second application of alpha, beta-meATP and subsequent 
MO application to the pulp. These results suggest that P2X3 and possibly also the 
P2X2/3 receptor subtypes in TSNC play a crucial role for the initiation and main-
tenance of central sensitization in brainstem nociceptive neurons [89]. Tooth pulp 
application of mustard oil (MO) induced a significant increase in glutamate release 
in TSNC. Intrathecal administration of apyrase or TNP-ATP (a P2X1, P2X3, P2X2/3 
receptor antagonist) alone significantly reduced the MO-induced glutamate release 
in the TSNC. Furthermore, the suppressive effects of apyrase on glutamate release 
were reduced by DPCPX (an adenosine A1 receptor antagonist) [89].
It had been reported that P2X3 receptor expressed in astrocytes in the TSNC 
participates in the development of craniofacial neuropathic pain induced by chronic 
constriction of the infraorbital nerve (CCI-ION) [90]. The number of P2X3-positive 
fine astrocytic processes and the density of P2X3 receptors in these processes was 
increased significantly in CCI-ION model and administration of MPEP, a specific 
mGluR5 antagonist, alleviated the mechanical allodynia and abolished the increase 
of P2X3 receptor expression in the fine astrocytic processes. Specific glial cell popu-
lations become activated in both trigeminal ganglia and brainstem in CFA-injection 
induced temporomandibular joint (TMJ) inflammation pain model. CFA-injected 
animals exhibited ipsilateral mechanical allodynia that is accompanied by a substan-
tial increase of GFAP-positive satellite glial cells and activation of resident macro-
phages in the trigeminal ganglia. The activated microglial cells were also observed in 
the ipsilateral TSNC [91]. In dental pulp, MO injection induced central sensitization 
model, it has been demonstrated that continuous intrathecal (i.t.) superfusion of the 
potent P2X7 receptor antagonists brilliant blue G or periodate-oxidized ATP could 
significantly attenuate the central sensitization. Specifically, central sensitization 
could be induced by superfusion of ATP and even more effectively produced by the 
P2X7 receptor agonist benzoylbenzoyl ATP. Consistent with the report that P2X7 
receptors are mostly expressed on microglia, superfusion of the microglial blocker 
minocycline abolished the MO-induced central sensitization. These novel findings 
suggest that activation of P2X7 receptors in microglia cells may be involved in the 
development of central sensitization in acute dental orofacial pain [92].
Microglial P2Y12 receptor is also reported to be involved in the central sensitiza-
tion of orofacial pain [93]. In a tongue cancer, pain model produced by squamous 
cell carcinoma (SCC) cell inoculation, microglia were strongly activated in TSNC, 
and administration of MRS2395 or minocycline reversed the associated nocicep-
tive behavior and microglial activation in SCC-inoculated rats. The increased 
activity of TSNC wide dynamic range nociceptive neurons was also recorded in 
SCC-inoculated rats. These findings suggest that SCC inoculation results in strong 
activation of microglia via P2Y12 receptor signaling in the TSNC that is associated 
with the increased excitability of TSNC nociceptive neurons and the development 
of central sensitization.
4.4 Adenosine signaling and dental orofacial pain
Purinergic P1 receptor signaling may also exist in trigeminal nerves and affects 
nociception processing. In 12 healthy female volunteers randomized, double-blind, 
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placebo-controlled, cross-over trial, the effect of A1 receptor agonist GR79236 
on trigeminal nociception processing was investigated. Activation of A1 recep-
tor with GR79236 inhibits trigeminal nociception in humans [94]. In a model of 
trigeminovascular nociceptive transmission, the superior sagittal sinus (SSS) was 
stimulated electrically, and the responding nociceptive units were recorded. It has 
been shown that intravenous administration of the highly selective adenosine A1 
receptor agonist, GR79236 had a dose-dependent inhibitory effect on SSS-evoked 
trigeminal nociceptive activity. Selective adenosine A1 receptor antagonist DPCPX 
abolished the neuronal inhibitory effect of GR79236 [95]. In another animal experi-
ment, adenosine decreased the amplitude of glutamatergic excitatory postsynaptic 
currents and increased the unpaired-pulse ratio suggesting that adenosine acts 
presynaptically to reduce glutamate release from primary afferents. Besides, the 
adenosine-induced inhibition of excitatory postsynaptic currents was impaired by 
a selective A1 receptor antagonist, DPCPX, and was mimicked by a selective A1 
receptor agonist CPA. These findings suggest that presynaptic A1 receptors decrease 
action potential-dependent glutamate release from primary trigeminal afferents 
onto TSNC neurons, and thus adenosine A1 receptors could be a potential target for 
the treatment of pain of orofacial tissues [96].
4.5 Ecto-nucleotidases in trigeminal nerves and orofacial pain
By the control of ATP degradation and adenosine generation, ecto-nucleotidases 
drive the shift from ATP-induced nociception to adenosine-induced analgesia 
[97]. Since ATP induces pain and pain sensitization via activation of P2X recep-
tors and adenosine mediates analgesia via activation of P1 receptors, existence of 
ecto-nucleotidases and their enzymatic activities in the trigeminal nociceptive 
pathway will affect the development and maintenance of dental orofacial pain. 
Recently we have demonstrated the expression and central terminal localization of 
ecto-nucleotidases (NTPDase3/CD73) in the trigeminal ganglia nociceptive neurons 
[64, 98]. Considering the pivotal role of purinergic singling in the pathogenesis of 
neuropathic pain and the preference expression and upregulation of purinergic 
receptors in the trigeminal nervous system, ecto-nucleotidase expression, and 
localization in trigeminal nerves might participate in the development of orofacial 
neuropathic pain.
Using histochemistry staining, ecto-ATPase and AMPase activities were detected 
in dental pulp odontoblast layer, Raschkow’s nerve plexus, and nerve bundles. 
Interestingly, in inflammatory dental pulp with pulpitis, enzymatic ecto-ATPase 
activity was significantly upregulated. Specifically, using immunohistochemistry 
and immunofluorescence staining, NTPDase2 is expressed in Shwann’s cells that 
encapsulate the Aβ and Aσ fibers, while that NTPDase3 and CD73 are detected in 
nociceptive nerve fibers in dental pulp [60, 64, 98].
Trigeminal ganglia contain both primary sensory neurons and satellite glial 
cells. Satellite glial cells encapsulate the ganglia neurons and are gap junction 
channel connected. Via intercellular interaction satellite glia cells affect neuronal 
excitability and impulse conduction in TG neurons. The ecto-ATPase activity was 
detected in TG cells. Specifically, NTPDase3 is expressed in TG neurons, including 
the nociceptive neurons, while NTPDase2 is expressed in TG satellite glial cells that 
encapsulated the TG neurons [60, 64, 98]. In addition, ecto-AMPases activity is also 
detected in TG cells and TG nerve fibers. It reveals that CD73 is expressed in TG 
neurons, including the nociceptive neurons [64]. By control of extracellular ATP 
degradation and adenosine generation, these enzymes would play a crucial role in 
orofacial pain signal processing by affecting the excitability, inhibition, and interac-
tion of TG neurons.
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TG nociceptive neurons project central nerve fibers to the brainstem and form 
synapses with the secondary nociceptive neurons in the nociceptive lamina of the 
TSNC. It has been well established that the nociceptive lamina in the brainstem or 
spinal cord is a pivotal region for pain signaling transmission, inhibition, modula-
tion, and sensitization. Interestingly, striking ecto-ATPase and ecto-AMPase activi-
ties were detected in brainstem TSNC nociceptive lamina. Immunohistochemistry 
studies confirmed the existence of immunoreactivity for NTPDase3 and CD73 in 
the nociceptive lamina. Furthermore, it has been demonstrated that incubation 
with specific anti-NTPDase3 or anti-CD73 antibodies, significantly reduced 
ecto-ATPase and acto-AMPase activities in TNSC nociceptive lamina, respectively 
[64, 98]. These findings suggest that NTPDase 3 and CD73 are the major enzymes 
responsible for ATP degradation and adenosine generation in TSNC nociceptive 
lamina. Since the neuronal plasticity and central sensitization mainly occurs at 
the central nociceptive lamina in neuropathic pain, the presence of NTPDase3 and 
CD73 in TNSC nociceptive lamina may also participate in the central sensitization 
mechanism in orofacial neuropathic pain.
The characteristic staining patterns for NTPDase3 and CD73 in the nociceptive 
lamia of TSNC indicate the presynaptic localization of these enzymes [64, 98]. This 
observation suggests that NTPDase3 and CD73 are produced at TG nociceptive 
neurons and then are transferred to the central presynaptic membranes along the 
afferent trigeminal nerves. Disruption of ecto-nucleotidase expression and presyn-
aptic localization caused by biological, chemical, or physical trigeminal insults such 
as virus infection, nerve fiber differentiation, and physical constriction//compres-
sion may attribute to pathogenesis mechanism in trigeminal neuralgia and other 
orofacial neuropathic pain [64, 98].
5. Conclusion
Purinergic signaling plays essential role in pain signal processing in the nocicep-
tive pathway from peripheral to central nerves. Via activation of P2X, P2Y, and P1 
receptors, ATP and its metabolites induced purinergic signaling participates in the 
nociceptive transduction, conduction, transmission, modulation, sensitization, and 
development of neuropathic pain. Ecto-nucleotidases are the predominant enzymes 
responsible for extracellular ATP degradation and adenosine generation that play 
essential role to drive the shift from ATP-induced pain to adenosine-induced anal-
gesia. In order to identify the role of purinergic signaling in dental orofacial pain, 
the existence of purinergic signaling and their regulation in the trigeminal nocicep-
tive pathway has yet to be identified.
Several ion channels and receptors that are prominent in craniofacial nocicep-
tive mechanisms have been identified on trigeminal primary afferent neurons. 
Many of these receptors and channels exhibit unusual distributions compared 
with extracranial regions. For example, expression of the ATP receptor P2X3 is 
strongly implicated in nociception and is more abundant on trigeminal primary 
afferent neurons than analogous extracranial neurons. P2X3 receptors are often 
co-expressed with the nociceptive neuropeptides CGRP and SP in trigeminal 
ganglia neurons. Co-expression of P2X3 receptor and other nociceptors (TRPV1, 
and ASIC3) in trigeminal neurons imply the existence of functional complexes that 
allow craniofacial nociceptive neurons to respond synergistically to altered ATP and 
other pain mediators. These observations indicate that trigeminal P2X3 receptor 
expression pattern differs markedly from dorsal root ganglion that may provide a 
clue to explain the unique properties of dental orofacial pain. Different expression 
and or regulation of purinergic signaling in the trigeminal nociceptive pathway may 
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attribute to a nociceptive mechanism of dentin hypersensitivity and dental orofacial 
pain. Identification of the underlying nociceptive mechanism will unveil potential 
targets for better treatment and management of dental orofacial pain.
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